Details of Disease

General Information of Disease (ID: DIS2R4Z0)

Disease Name	Prurigo nodularis
Disease Class	EC91: Prurigo
Definition	Prurigonodularis (PN) is a skin disease in which hard crusty lumps are formed on the skin that itches intensely. Repetitive rubbing, scratching, and touching results in more lesions in the skin. The itching is so intense that people scratch themselves to the point of bleeding or pain. The lumps formed in the skin are hard, and have about a half inch across, with a dry and rough top that is often scratched open. They tend to be located in the areas most easily reached and are worse on the outer sides: arms, shoulders and legs. The trunk, face and even palms can also be affected. The exact cause is unknown but some factors triggering PN include liver and kidneys problems, nervous and mental conditions and other skin diseases. Prurigo nodulares, in some cases, can be seen in other diseases such as lymphoma, chronic autoimmune cholestatic hepatitis, HIV infection, severe anemia,or a chronic kidney disease-related itching known as uremic pruritus. Treatment is very difficult, and may include corticoids, antihistaminic and other medication such as thalidomide and similar (Lenalidomide). In some cases, cryotherapy, photochemotherapy and habit reversal therapy for the itch-scratch cycle has improved the symptoms. PN can last for many years, and the itching is so intense that may affect all the everyday activities.
Disease Hierarchy	DIS9YPUQ: Dermatological disease DIS2R4Z0: Prurigo nodularis
ICD Code	ICD-11 ICD-11: EC91.0 ICD-10 ICD-10: L28.1 Expand ICD-11 'EC91.0 Expand ICD-10 'L28.1
Disease Identifiers	MONDO ID MONDO_0026045 UMLS CUI C0263353 MedGen ID 120471 SNOMED CT ID 63501000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Nalbuphine	DMOSQGU	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Serlopitant	DM5VH6U	Phase 3	NA	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)